Report cover image

CSL Vifor - Strategic SWOT Spotlight

Publisher Quaintel Research
Published Jun 20, 2025
Length 92 Pages
SKU # QTELR20123856

Description

Report Spotlight

CSL Vifor - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The CSL Vifor's business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.

Key Highlights

CSL Vifor, established in 1927, is a global specialty pharmaceutical company headquartered in Glattbrugg, Switzerland. Specializing in iron deficiency and nephrology, CSL Vifor offers a broad portfolio aimed at preserving renal function, managing complications, and improving patients' quality of life. With a presence in over 100 countries across North and South America, Europe, the Middle East, and the Asia-Pacific region, the company operates through subsidiaries and joint ventures, including Vifor Fresenius Medical Care Renal Pharma and Sanifit Therapeutics. CSL Vifor is part of the CSL Group, a global biotechnology leader founded in 1916, renowned for its dynamic portfolio of lifesaving medicines

CSL Vifor in the News:-
  • 03-Mar-2025 - CSL Seqirus and Esperion Sign Licensing Agreement to commercialise Nexletol(bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) in Australia and New Zealand
  • 26-Feb-2025 - Swissmedic Approves CSL Behring's ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
  • 20-Feb-2025 - CSL Receives Approval in Japan for ANDEMBRY(garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
  • 14-Feb-2025 - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine
  • 13-Feb-2025 - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Scope

Company Fundamentals:- These fundamentals offer valuable insights into CSL Vifor's operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.

Reasons to Buy
  • Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Table of Contents

92 Pages
Table of Contents
Tables
Charts
CSL Vifor - Key Company Facts
CSL Vifor - Company Description
CSL Vifor - Top Executives
CSL Vifor - Head Office & Locations
Head Office - Country
CSL Vifor - Products and Services
Products
Services
CSL Vifor - Corporate Strategy
CSL Vifor - Business Description
Iron Deficiency
Nephrology
Dialysis
CSL Vifor - ESG Spotlight
Environment
Social
Corporate Governance
CSL Vifor - SWOT Spotlight
Overview
Strengths
Weaknesses
Opportunities
Threats
Competing Players
Snapshot of Competing Players
Johnson & Johnson Services, Inc.
Key Company Facts
Company Description
Johnson & Johnson Services, Inc. - SWOT Spotlight
Johnson & Johnson Services, Inc. - PESTLE Spotlight
Key Financials
Share Price Trend - Jan-2024 to Jun-2025 (Average Share Closing Price)
Key Financial Ratio Analysis
Key Financial Ratio
Charts
Activity Ratio
Charts
Growth Ratios
Charts
Leverage Ratio
Charts
Liquidity Ratio
Charts
Profitability Ratio
Charts
McKesson Europe AG
Key Company Facts
Company Description
Novartis AG
Key Company Facts
Company Description
Novartis AG - SWOT Spotlight
Key Financials
Share Price Trend - May-2024 to Jun-2025 (Average Share Closing Price)
Key Financial Ratio Analysis
Key Financial Ratio
Charts
Activity Ratio
Charts
Growth Ratios
Charts
Leverage Ratio
Charts
Liquidity Ratio
Charts
Profitability Ratio
Charts
Tecan Group Ltd
Key Company Facts
Company Description
Key Financials
Share Price Trend - Jan-2024 to Jun-2025 (Average Share Closing Price)
Key Financial Ratio Analysis
Key Financial Ratio
Charts
Activity Ratio
Charts
Growth Ratios
Charts
Leverage Ratio
Charts
Liquidity Ratio
Charts
Profitability Ratio
Charts
Stada Arzneimittel AG
Key Company Facts
Company Description
CSL Vifor - In the News
03-Mar-2025- CSL Seqirus and Esperion Sign Licensing Agreement to commercialise Nexletol(bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) in Australia and New Zealand
26-Feb-2025- Swissmedic Approves CSL Behring's ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
20-Feb-2025- CSL Receives Approval in Japan for ANDEMBRY(garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
14-Feb-2025- European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine
13-Feb-2025- European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
07-Feb-2025- CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
24-Jan-2025- Australia's Therapeutic Goods Administration (TGA) Approves Registration of CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks
24-Oct-2024- Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships
17-Oct-2024- CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy
17-Oct-2024- CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us